Pathstone Holdings’s Vaxcyte PCVX Stock Holding History

Pathstone Holdings’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Sell	23,876 -3,290	-12%	-$179K	﹤0.01%	1336
2026 Q1	$1.58M	Buy	27,166 +2,937	+12%	+$159K	0.01%	1151
2025 Q4	$1.12M	Buy	24,229 +2,140	+10%	+$95.7K	﹤0.01%	1351
2025 Q3	$796K	Buy	22,089 +1,459	+7%	+$48.3K	﹤0.01%	1547
2025 Q2	$671K	Sell	20,630 -2,117	-9%	-$69.4K	﹤0.01%	1580
2025 Q1	$859K	Sell	22,747 -8,794	-28%	-$703K	﹤0.01%	1461
2024 Q4	$2.58M	Buy	31,541 +1,014	+3%	+$101K	0.01%	842
2024 Q3	$3.49M	Buy	30,527 +2,154	+8%	+$194K	0.02%	694
2024 Q2	$2.14M	Buy	28,373 +5,100	+22%	+$347K	0.01%	896
2024 Q1	$1.59M	Buy	23,273 +19,516	+519%	+$1.35M	0.01%	1026
2023 Q4	$236K	Buy	+3,757	New	+$195K	﹤0.01%	1974

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Pathstone Holdings's PCVX Position: Q2 2026 in Review

Pathstone Holdings reduced its Vaxcyte (PCVX) stake by 12% in Q2 2026, selling an estimated $179K and leaving 23,876 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1336.

Pathstone Holdings first reported a position in PCVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.49M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Pathstone Holdings held 23,876 shares of Vaxcyte worth $1.39M as of Q2 2026.
Pathstone Holdings sold 3,290 Vaxcyte shares in Q2 2026, an estimated $179K.
Vaxcyte made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1336 holding.
Pathstone Holdings first reported a position in Vaxcyte in Q4 2023 and has held it in 11 quarters since.
Pathstone Holdings's Vaxcyte position peaked at $3.49M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.